ALACHUA, FL--(Marketwire - December 14, 2007) - Oragenics, Inc. (AMEX: ONI), a biotechnology development company focused on infectious diseases and cancer, announced today that it has been notified by the European Patent Office of its intention to grant a European patent for “Identification of Microbial Polynucleotides Expressed During Infection of a Host” or the In Vivo Induced Antigen Technology, IVIAT™. Oragenics intends to validate the patent in key European jurisdictions.
